From Financialpost · · 1m 30s
Spruce Biosciences Presents MPS IIIB Data at CNS Meeting
Spruce Biosciences to share natural history study results for MPS IIIB at Child Neurology Society meeting.
In brief
Spruce Biosciences to share natural history study results for MPS IIIB at Child Neurology Society meeting. Spruce Biosciences will present natural history data for MPS IIIB at the 55th Child Neurology Society Annual Meeting in October 2026. Originally reported by Financialpost.
Spruce Biosciences Announces Data Presentation
Spruce Biosciences, a late-stage biopharmaceutical company focused on neurological disorders with unmet medical need, will present natural history data for MPS IIIB at the 55th Child Neurology Society Annual Meeting.
Study 250-902 Details
Study 250-902, a prospective multicenter multinational noninterventional longitudinal natural history study, characterizes disease progression in pediatric participants with severe non-attenuated Sanfilippo Syndrome Type B.
Presentation Schedule
The poster presentation occurs October 15, 2026, from 12:30 p.m. to 1:45 p.m. EDT and 5:30 p.m. to 7:30 p.m. EDT at the Child Neurology Society Annual Meeting in Montréal, Québec, Canada.
Presenters and Authors
Ilyas Okur, M.D., Professor of Pediatrics at Gazi University Faculty of Medicine in Ankara, Türkiye, will present the study with a team of authors including Fatih Ezgu, M.D., Yin-Hsiu Chien, M.D., Ph.D., and others.
Spruce Biosciences Focus
Spruce Biosciences develops tralesinidase alfa enzyme replacement therapy (TA-ERT) for MPS IIIB, a pediatric neurodegenerative disorder with no FDA-approved treatments.
Regulatory Designations
TA-ERT has received Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation from the FDA, as well as Orphan Drug Designation in the European Union.
The bottom line
Spruce Biosciences will present natural history data for MPS IIIB at the 55th Child Neurology Society Annual Meeting in October 2026.
